Buyback Announcements and News

7/17/2026

Follow-up: Butterfly Network Founder/Director Jonathan Rothberg disclosed the sale of ~5.21M shares in total since 14-Jul - 144 ($6.62, 0.00)

  • We had previously reported on 15-Jul, Rothberg's sale of 1.73M shares through a form 144 filing and, including that 15-Jul sale, today's filing disclosed a total sale of ~5.21M shares this week.

7/17/2026

Morgan Stanley CFO Sharon Yeshaya discloses sale of ~15.6K shares of common stock - Form 4 ($215.50, 0.00)

  • Following the disclosure, Yeshara beneficially owns ~136.8K shares of common stock

7/17/2026

Value Line renews share repurchase program for up to $2M ($41.00, 0.00)

  • The new repurchase program, which replaces the October 2025 program, has no set price limit and no expiration date.

7/17/2026

Insider transaction: Greenland Mines Chief Financial Officer Jeff Leblanc discloses purchase of 1.4M shares - Form 4 ($0.20, +0.03)

  • Leblanc beneficially owns 4.8M shares of common stock following the transaction.

7/17/2026

Insider transaction: Jefferies Financial Group holder SMFG discloses purchase of 5.9M shares - Form 4 ($55.80, 0.00)

  • Sumitomo Mitsui Financial Group beneficially owns 8.6M shares of common stock following the transaction.
  • The filing notes the price paid by an affiliate of Sumitomo Mitsui for the reported securities is subject to adjustment following an approximately two-month reference period pursuant to an agreement previously entered into between an affiliate of the holder and an unaffiliated third-party.
  • StreetAccount notes the companies announced in September 2025 that Sumitomo Mitsui agreed to increase its equity ownership in Jefferies to up to 20% in the open market. Reports in March 2026 indicated Sumitomo Mitsui had no immediate plan to take over Jefferies following prior reports of a potential acquisition.

7/16/2026

Dimerix acquires Phase 2-ready asset DMX-652 from Mission Therapeutics; enters into loan facility agreement (A$0.24, 0.00)

  • M&A:
    • The new asset, DMX-652, which expands Dimerix's pipeline in rare kidney disease, is a novel first and best-in-class therapeutic candidate, initially targeting the prevention of acute kidney injury
      • The DMX-652 acquisition includes assignment of the composition of matter patent, an open IND in the US with a Phase 2 clinical trial protocol which has received approval to proceed by the FDA, as well as sufficient pharmaceutical grade (GMP) drug product for the Phase 2 trial and all manufacturing methodology
    • Terms of the agreement
      • Under the terms of the agreement, Dimerix will have sole ownership and control development of DMX-652.
        • Dimerix will pay a $5M upfront acquisition payment to UK based Mission Therapeutics within 30 days of signing; up to $47M deferred acquisition payment payable on upon success of predefined clinical development milestones; $40M on product marketing approval; $25M on approval in a second indication; and up to $175M on certain successbased sales milestones. Dimerix will pay 8-10% royalty on global net sales if made by Dimerix, or 2.5%- 5% on net sales if made by a third-party sub-licensee.
  • Funding
    • Dimerix entered into a loan facility agreement with SKIPTAN Pty Ltd, an associate of Mr Meurs (a substantial shareholder of the company).
      • The Lender has agreed to advance A$10M to the company with any potential drawdown taking place at the company's discretino
    • Funded for ACTION3 trial Dimerix confirms that it is funded through to completion of the ACTION3 Phase 3 trial inDMX-200 , as well as initiation of the Phase 2 clinical trial in DMX-652 through:
      • Existing cash reserves;
        • A$14M upfront payment to be received from Everest Medicines for commercial rights to Greater China, South Korea and Southeast Asia; and
        • A$10M through the binding Loan agreement, with any draw-down to take place at the company's discretion.
        • Negotiations to access up to a further A$40M in non-dilutive funding (anticipated to be on substantially similar terms to the loan facility) are progressing and such funding would extend the company's cash runway
  • Conference call:;

7/16/2026

Caring Brands discloses securities purchase agreement - 8-K ($1.28, 0.00)

  • On 10-Jul-26, Caring Brands entered into a Securities Purchase agreement with one accredited investor for a private investment in public equity (PIPE offering) of 443.2133 shares of its Series A Convertible Preferred Stock par value $0.001 per share, with a stated value $1,000.00 per share, equating to 443.213 Series A Convertible Preferred Shares which equates to a purchase price of $950 per share of Series A Preferred Stock with a stated value of $1,000 per share, after factoring in an original issue discount of 5%.
  • The Series A Preferred Stock is convertible into common stock.at a conversion price of $0.40 per share.
  • The company also issued an aggregate of 1.1M warrants to acquire up to 1.1M shares of common stock at an exercise price of $0.40 per share.
  • The Common Warrants issued in the PIPE offering are exercisable immediately and will expire five years from the date of issuance.
  • The exercise of the Common Warrants and the conversion of the Series A Preferred Stock are both subject to beneficial ownership limitations set by the holder.
  • The aggregate purchase price was $400,000.
  • In addition, the company will not issue any shares upon the exercise of the Warrants or the conversion of the Series A Preferred Stock to the extent that the aggregate issuances thereunder would exceed an aggregate of 19.99% of the company's outstanding shares of common stock without first obtaining shareholder approval.
  • The PIPE offering closed on 10-Jul-26, with aggregate gross proceeds totaling ~$400,000.
  • The company intends to use $150,000 of the net proceeds from the PIPE offering to retire an aggregate of 150,000 shares of the company's common stock owned by BK Investments LLC, an entity owned by Brian John, the company's Chairman and acting CFO, pursuant to a Stock Purchase agreement, dated as of 10-Jul-26 and the remainder of the proceeds shall be used for general corporate and working capital purposes.

7/16/2026

Valero Energy' board authorizes repurchase of up to additional $5.0B - 8-K ($300.26, 0.00)

  • On 25-Feb-26, the board of Valero Energy Corporation authorized Valero to purchase shares of its outstanding common stock for a total cost of up to $2.5B with no expiration date.
  • As of 30-Jun-26, Valero had $1.4B remaining available for purchase under the February 2026 Program.
  • On 16-Jul-26, the board authorized Valero to purchase shares of its outstanding common stock for a total cost of up to $5.0B with no expiration date, which is in addition to the amount remaining under the February 2026 Program.

7/16/2026

Genesis Energy LP increases quarterly dividend by 11.1% to $0.20 from $0.18; repurchases 250K common units ($14.43, 0.00)

  • Payable 14-Aug-26; record 31-Jul-26
  • Genesis repurchased 250,000 common units at a weighted average price of $14.57 per unit, for a total of ~$3.6M during Q2 of 2026

7/16/2026

Arbutus initiates international patent infringement enforcement actions against Pfizer and BioNTech, receives first payment from Moderna settlement agreement and announces intent to return capital to shareholders ($4.56, 0.00)

  • Arbutus Biopharma Corporation and its exclusive licensee, Genevant Sciences GmbH (a subsidiary of Roivant Sciences Ltd. (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their LNP technology against Pfizer Inc. (PFE), BioNTech SE (BNTX) and certain of their affiliates. Arbutus and Genevant are seeking monetary relief, as well as injunctions against Pfizer/BioNTech's mRNA-LNP COVID-19 vaccines and any other products that would infringe the asserted patents.
  • The cases are:
    • Canada: Federal Court of Canada File No. T-3200-26, seeking a permanent injunction and damages or, if Arbutus and Genevant elect, an accounting of Pfizer/BioNTech's profits, attributable to infringement of Canadian Patent No. 2,721,333
    • Unified Patent Court: Case PR-UPC-CFI-0002562/2026, seeking permanent injunctions, as well as monetary damages, which can include recovery of Pfizer/BioNTech's unfair profits from infringement of EP 4 241 767
    • UPC: Case PR-UPC-CFI-0002566/2026, seeking permanent injunctions, as well as monetary damages, which can include recovery of Pfizer/BioNTech's unfair profits from infringement of EP 4 495 237
  • The UPC actions seek relief for: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovenia, Spain, and Sweden.
  • Today's actions expand on Arbutus and Genevant's ongoing enforcement proceeding in the U.S. District Court for the District of New Jersey, seeking fair compensation for Pfizer/BioNTech's infringement of five U.S. patents in the manufacture and sale of Pfizer/BioNTech's mRNA-LNP COVID-19 vaccines.
  • Arbutus also announced the receipt on 8-Jul-26 of ~$178M from Moderna, Inc. (MRNA), representing the company's share of the noncontingent payment under the settlement agreement entered into with Moderna to resolve all global patent infringement litigation with Moderna related to Moderna's COVID-19 vaccines. The payment from Moderna includes reimbursement of the company's litigation costs in accordance with the company's license agreement with Genevant. Arbutus also expects to receive a dividend from Genevant's parent in Q3 2026, related to its ownership of ~16% of the outstanding common equity of Genevant's parent.
  • Arbutus is also announcing that it expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to ~$230M of the company's common shares, which repurchases may come in the form of a tender offer, open market purchases, privately negotiated transactions, accelerated share repurchases or other means. The specific form(s) of any such transaction(s) remains subject to the approval of the company's board. Any repurchase will not commence until after receipt of the expected dividend from Genevant's parent in Q3 2026. No assurance can be given that any such repurchase activity will occur in Q3 2026, or at all.